Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis

Hepatology

Volumn 56, Issue 4, 2012, Pages 1371-1379

  Giannini, Edoardo G ^a   Marenco, Simona ^a   Borgonovo, Giacomo ^a   Savarino, Vincenzo ^a   Farinati, Fabio ^b   Del Poggio, Paolo ^c   Rapaccini, Gian Ludovico ^d   Anna Di Nolfo, Maria ^e   Benvegnù, Luisa ^b   Zoli, Marco ^f   Borzio, Franco ^g   Caturelli, Eugenio ^h   Chiaramonte, Maria ⁱ   Trevisani, Franco ^f   Bernardi, Mauro ^j   Biselli, Maurizio ^j   Cassini, Romina ^j   Caraceni, Paolo ^j   Domenicali, Marco ^j   Erroi, Virginia ^j   Frigerio, Marta ^j   Gramenzi, Annagiulia ^j   Lenzi, Barbara ^j   Magalotti, Donatella ^j   Balsamo, Claudia ^j   Di Marco, Maria ^j   Vavassori, Elena ^j   Gilardoni, Lodovico ^j   Mattiello, Mario ^j   Alberti, Alfredo ^j   Gatta, Angelo ^j   Gios, Maurizio ^j   Giacomin, Anna ^j   Vanin, Veronica ^j   Pozzan, Caterina ^j   Maddalo, Gemma ^j   Ravaioli, Matteo ^j   Cucchetti, Alessandro ^j   Giampalma, Emanuela ^j   Golfieri, Rita ^j   Mosconi, Cristina ^j   Renzulli, Matteo ^j   Ghittoni, Giorgia ^j   Roselli, Paola ^j   Bosco, Giulia ^j   more..

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c TREVIGLIO HOSPITAL   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e BOLOGNINI HOSPITAL   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g FATEBENEFRATELLI HOSPITAL   (Italy)

^h BELCOLLE HOSPITAL   (Italy)

ⁱ SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALCOHOL; ALPHA FETOPROTEIN; BILIRUBIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER SIZE; CANCER SURVIVAL; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; RECEIVER OPERATING CHARACTERISTIC; SMALL CELL CARCINOMA;

EID: 84867182885     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25814     Document Type: Article

References (49)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-S50.
3. Sherman M. Hepatocellular carcinoma: screening and staging. Clin Liver Dis 2011; 15: 323-334.
4. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422.
5. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. HEPATOLOGY 2000; 31: 330-335.
6. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126: 1005-1014.
7. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010; 53: 291-297.
8. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
9. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4: 439-474.
10. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. HEPATOLOGY 2011; 53: 1020-1022.
11. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009; 29: 502-510.
12. Pompili M, Rapaccini GL, Covino M, Pignataro G, Caturelli E, Siena DA, et al. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. Cancer 2001; 92: 126-135.
13. Huo TI, Huang YH, Lui WY, Wu JC, Lee PC, Chang FY, et al. Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center. Oncol Rep 2004; 11: 543-550.
14. Kim SH, Park JW, Jang JS, Kim HJ, Shin WG, Kim KH, et al. Prognostic values of α-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma. A prospective study. J Clin Gastroenterol 2009; 43: 482-488.
15. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
16. Huo TI, Lee SD. Role of the model for end-stage liver disease and serum α-fetoprotein as predictors for hepatocellular carcinoma. Liver Int 2006; 26: 1300-1301.
17. Santi V, Buccione D, Di Micoli A, Fatti G, Frigerio M, Farinati F, et al. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J Hepatol 2012; 56: 397-405.
18. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.
19. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
20. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48, 900 necropsies. Cancer 1954; 7: 462-503.
21. Pirisi M, Leutner M, Pinato DJ, Avellini C, Carsana L, Toniutto P, et al. Reliability and reproducibility of the Edmondson grading of hepatocellular carcinoma using paired core biopsy and surgical resection specimens. Arch Pathol Lab Med 2010; 134: 1818-1822.
22. Kim DY, Kim JW, Kuromatsu R, Ahn SH, Torimura T, Sherman M. Controversies in surveillance and early diagnosis of hepatocellular carcinoma. Oncology 2011; 81(Suppl 1): 56-60.
23. Sherman M. α-Fetoprotein. An obituary. J Hepatol 2001; 34: 603-605.
24. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, et al. Diagnostic and prognostic role of α-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006; 101: 524-532.
25. Bayati N, Silverman AL, Gordon SC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol 1998; 93: 2452-2456.
26. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138: 493-502.
27. Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, et al. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol 2012; 107: 64-74.
28. Marrero J, El-Serag HB. Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases. HEPATOLOGY 2011; 53: 1060-1061.
29. Giannini EG, Farinati F, Trevisani F. Alpha-fetoprotein in hepatocellular carcinoma surveillance: wake not the dead. HEPATOLOGY 2011; 54: 376-377.
30. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Cancer 1989; 64: 1700-1707.
31. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. HEPATOLOGY 1998; 28: 751-755.
32. Rapaccini GL, Pompili M, Caturelli E, Covino M, Lippi ME, Beccaria S, et al. Hepatocellular carcinomas <2 cm in diameter complicating cirrhosis: ultrasound and clinical features in 153 consecutive patients. Liver Int 2004; 24: 124-130.
33. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005; 43: 434-441.
34. Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, et al. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol 2007; 22: 669-675.
35. Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009; 27: 5734-5742.
36. Han K, Tzimas GN, Barkun JS, Metrakos P, Tchervenkov JL, Hilzenrat N, et al. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol 2007; 21: 39-45.
37. Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010; 10: 129-137.
38. Merani S, Majno P, Kneterman NM, Berney T, Morel P, Mentha G, et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011; 55: 814-819.
39. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-240.
40. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg 2007; 245: 51-58.
41. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
42. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48: S20-S37.
43. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005; 25: 133-142.
44. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? HEPATOLOGY 2008; 47: 82-89.
45. Santambrogio R, Opocher E, Zuin M, Selmi C, Bertolini E, Costa M, et al. Surgical resection versus laparoscopic radiofrequency ablation in patients with hepatocellular carcinoma and Child-Pugh class a liver cirrhosis. Ann Surg Oncol 2009; 16: 3289-3298.
46. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13: e11-22.
47. Vitale A, Morales RR, Zanus G, Farinati F, Burra P, Angeli P, et al. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncol 2011; 12: 654-662.
48. De Bac C, Stroffolini T, Gaeta GB, Taliani G, Giusti G. Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: a multicenter Italian study. HEPATOLOGY 1994; 20: 1225-1230.
49. Stroffolini T, Andreone P, Andriulli A, Ascione A, Craxi A, Chiaramonte M, et al. Characteristics of hepatocellular carcinoma in Italy. J Hepatol 1998; 29: 944-952.